%0 Journal Article
%T Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
%A Singh N
%A Temin S
%A Baker S
%A Blanchard E
%A Brahmer JR
%A Celano P
%A Duma N
%A Ellis PM
%A Elkins IB
%A Haddad RY
%A Hesketh PJ
%A Jain D
%A Johnson DH
%A Leighl NB
%A Mamdani H
%A Masters G
%A Moffitt PR
%A Phillips T
%A Riely GJ
%A Robinson AG
%A Rosell R
%A Schiller JH
%A Schneider BJ
%A Spigel DR
%A Jaiyesimi IA
%J J Clin Oncol
%V 40
%N 28
%D 10 2022 1
%M 35816666
%F 50.717
%R 10.1200/JCO.22.00824
%X To provide evidence-based recommendations updating the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations.<BR>ASCO updated recommendations on the basis of an ongoing systematic review of randomized control trials from 2020 to 2021.<BR>This guideline update reflects changes in evidence since the previous update. Two studies provide the evidence base. Outcomes of interest include efficacy and safety.<BR>For patients with an anaplastic lymphoma kinase rearrangement, a performance status (PS) of 0-2, and previously untreated NSCLC, clinicians should offer alectinib or brigatinib or lorlatinib. For patients with an anaplastic lymphoma kinase rearrangement, a PS of 0-2, and previously untreated NSCLC, if alectinib, brigatinib, or lorlatinib are not available, clinicians should offer ceritinib or crizotinib. For patients with a RET rearrangement, a PS of 0-2, and previously untreated NSCLC, clinicians may offer selpercatinib or pralsetinib. In second line, for patients with a RET rearrangement who have not received RET-targeted therapy, clinicians may offer selpercatinib or pralsetinib.Additional information is available at www.asco.org/thoracic-cancer-guidelines.